Navigation Links
Kendle Announces Details Regarding Third Quarter 2010 Earnings Conference Call and Webcast

CINCINNATI, Oct. 18 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) announced today it will release its third quarter 2010 financial results after the market closes on Monday, Nov. 8, 2010. The Company will host a telephone conference call and simultaneous webcast on Tuesday, Nov. 9 at 8:30 a.m. Eastern Time. A question and answer session will follow.

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 946-0709. Participants outside North America should dial (719) 457-2632. All participants should enter conference ID number 5419062. A replay will be available through 5 p.m. Eastern Time on Dec. 9, 2010, by dialing (888) 203-1112 in North America or 719-457-0820 outside of North America and entering conference ID number 5419062.

Webcast Instructions

To access the live webcast, visit Instructions for accessing the webcast are provided at the site. The webcast will be archived at (click on "For Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Dec. 9, 2010.  Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
2. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
3. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
4. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
5. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
6. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
7. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
8. Kendle Launches New Global Biostatistics Infrastructure
9. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
10. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
11. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... heating products business. Cozy Products explains what this means for business moving forward. , ... the Cozy Products business model: to sell personal heaters that reduce energy consumption, are ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... , ... Since its launch in 2012, the Regenestem brand ... therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent and ... , Organizations are required to hold a registered trademark in order to make ...
Breaking Medicine News(10 mins):